Antitrust Law Daily Wrap Up, CONSUMER PROTECTION NEWS: FTC sues Amare Global over dietary supplement and income claims, (Jun 3, 2026)

By Patricia K. Ruiz, J.D.

The FTC alleges deceptive marketing and misleading earnings representations targeting consumers and parents.

The FTC has sued Amare Global Holdings Inc. and three executives, alleging the company deceptively marketed dietary supplements as treatments for mental health conditions and misled consumers about income opportunities. The complaint centers on claims that products marketed for both adults and children could treat or mitigate conditions such as depression, anxiety, and ADHD, as well as representations that participants in the company’s multi-level marketing program could reliably earn income, according to the agency (FTC v. Amare Global Holdings, Inc., No. 2:26-cv-05900 (C.D. Cal. June 2, 2026)).

Amare Global Holdings, Inc. marketed products—including the Happy Juice Product Pack, Kids Mood+, and Kids Happy Juice—as capable of improving or treating mental health conditions in both adults and children. The complaint alleged that Amare operated a nationwide multi-level marketing (MLM) program selling dietary supplements through a network of “brand partners,” who promote products and recruit additional sellers. Amare and its distributors allegedly promoted the supplements as able to treat or mitigate depression, anxiety, and ADHD, including claims directed at parents seeking help for children with such conditions.

The FTC further alleged that these products were promoted as affecting the “gut-brain axis,” with representations that they could regulate neurotransmitters such as serotonin, dopamine, and GABA, and hormones such as cortisol, thereby improving mental health outcomes. The FTC asserts these claims were false, misleading, or not supported by competent and reliable scientific evidence.

The complaint details extensive marketing through social media platforms, where Amare and its brand partners allegedly disseminated claims that the supplements were “clinically proven,” “scientifically backed,” or capable of replacing prescription medications. In some instances, brand partners claimed the products could reduce the risk of suicide in children or allow users to discontinue psychiatric medications.

In a statement accompanying the filing, the FTC emphasized the alleged risks of such representations, asserting that the claims were “not only deceptive but dangerous,” particularly where they targeted parents of children with serious mental health conditions.

According to the complaint, Amare distributed marketing materials and training to its brand partners and relied on them to promote products and recruit additional sellers. The FTC alleges the company was aware that brand partners were making unsubstantiated or exaggerated claims and nonetheless failed to take meaningful action to stop or correct those representations.

The FTC also alleges that two defendants—the company’s former chief science officer and its founding brand partner—were subject to prior FTC orders prohibiting false or unsubstantiated claims, yet continued to make or facilitate such representations through Amare’s business operations.

Misrepresentations. In addition to health claims, the FTC challenges representations about earnings in Amare’s MLM program. The agency alleges that the company and its brand partners promoted participation as a realistic path to earning income, including claims that participants could make at least $500 per month or achieve significant or “life-changing” income.

The complaint alleges those income claims were misleading, citing company data indicating that only a small fraction of brand partners achieved such earnings. According to the FTC, a typical participant earned approximately $25 per month before expenses, based on Amare’s own income disclosures.

The FTC further alleges that Amare promoted its compensation plan in ways that suggested participants could generate “passive income,” financial independence, or substantial earnings despite data showing otherwise. The complaint also alleges that brand partners frequently made income representations without disclosing that such outcomes were atypical.

Claims. The agency asserts three counts under the FTC Act. Count I alleges deceptive health claims, including representations that the products can regulate hormones or treat depression, anxiety, and ADHD. Count II alleges deceptive income claims, including representations that participants are likely to earn specified or substantial income. Count III alleges that defendants provided the means and instrumentalities for deception by supplying marketing materials and guidance used by distributors.

The FTC alleges consumers “are suffering, have suffered, and will continue to suffer substantial injury” as a result of the conduct and seeks a permanent injunction and additional relief.

Companies: Amare Global Holdings, Inc.; M3 Ventures West, Inc.; Bioamity Global LLC

News: Advertising ConsumerProtection FederalTradeCommissionNews CaliforniaNews